MKMasataka Kuwana

Masataka Kuwana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masataka Kuwana has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Yuka Okazaki

    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    6 shared publications
  • Tsutomu Takeuchi

    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo

    4 shared publications
  • Hiroshi Miyazaki

    Innovative Drug Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Takasaki, Japan

    2 shared publications
  • Kana Hoshino

    Keio University School of Medicine Tokyo Japan

    2 shared publications
  • Noriyuki Seta

    Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    2 shared publications
  • Takashi Satoh

    Keio University School of Medicine Tokyo Japan

    2 shared publications

Latest Publications

  • Glomerulomegaly in lupus nephritis: a prognostic marker for renal outcomes

    by Hironari Hanaoka, Masataka Kuwana, Tsutomu Takeuchi

    AimGlomerulomegaly refers to the abnormal enlargement of glomeruli and is associated with an increased risk of progressive chronic kidney disease (CKD). However, it has rarely been investigated in lupus nephritis (LN). We therefore assessed glomerulomegaly as a prognostic factor for renal pathology.MethodPatients with class III or IV LN were retrospectively recruited and divided into two groups according to complete renal response (CR) at 3 years after the initiation of induction therapy. Baseline clinical and renal pathological findings were compared to identify prognostic factors, and patients were followed for up to 10 years to assess long‐term renal outcomes.ResultsNineteen patients with and 19 without CR on 3‐year follow‐up were analyzed. Long‐term disease duration and high levels of proteinuria were frequently observed in patients without CR (P = 0.03 and P = 0.01, respectively) at baseline compared to those with CR. On renal pathological analysis, a significantly higher proportion of patients without CR had enlarged glomeruli than those with CR (P = 0.03) in analysis of segmentally or minimally affected glomeruli. On 10‐year follow‐up, a higher proportion of patients without enlarged glomeruli maintained CR compared to those with enlarged glomeruli (P = 0.004). Further, glomerular area and disease duration were significantly correlated (P = 0.04).ConclusionsEnlarged segmentally or minimally affected glomeruli at diagnosis of LN might predict a worse renal prognosis at 3 years after induction therapy. Mechanical glomerular injury might influence clinical outcomes.


  • Early achievement of complete renal response predicts good long-term renal outcome and low systemic damage in newly diagnosed lupus nephritis class III or IV

    by Hironari Hanaoka, Yuko Kaneko, Masataka Kuwana, Tsutomu Takeuchi

    Objective. To identify predictors of long-term renal prognosis after induction therapy in patients with newly diagnosed lupus nephritis class III or IV. Methods. We retrospectively studied patients with newly diagnosed lupus nephritis class III or IV. We divided them into two groups according to the complete renal response (CR) status at 3 years after induction therapy. We compared baseline clinical characteristics, renal pathological findings, and time to achieve CR, and identified predictors. Patients were followed up for to 10 years to assess long-term systemic damage. Results. Eighteen patients with CR and 9 with non-CR were included. There were no significant differences in baseline characteristics. Early CR, which was defined as achieving CR at 3 months after induction therapy, was significantly associated with maintaining CR at 3 years (p = 0.012). Patients with early CR less frequently had flare in systemic manifestation compared with those without over 10 years (p = 0.026). Deterioration of systemic damage was observed more often in non-early CR patients than early CR patients at 10 years (p = 0.029). Conclusion. Achieving CR at 3 months after induction therapy may predict CR at 3 years, reduced organ damage, and a low incidence of disease flare for 10 years.


  • Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosis–Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement

    by Kenzou Kaji, Noreen Fertig, Thomas A. Medsger, Takashi Satoh, Kana Hoshino, Yasuhito Hamaguchi, Minoru Hasegawa, Mary Lucas, Andrew Schnure, Fumihide Ogawa, et al.

    Objective. This study was conducted to identify and characterize a novel systemic sclerosis (SSc)‐related autoantibody directed against a complex consisting of RuvBL1 and RuvBL2 (RuvBL1/2) and to assess its clinical correlations. Methods. We first analyzed 316 consecutive patients with SSc who were evaluated at Kanazawa University Hospital. Controls included 290 patients with other connective tissue diseases, interstitial lung disease alone, or autoimmune hepatitis, and 50 healthy subjects. Autoantibody specificities were analyzed using RNA and protein immunoprecipitation assays. Autoimmune targets were affinity‐purified using patients' sera and subjected to liquid chromatography‐mass spectrometry. SSc patients in another institution in Japan and the University of Pittsburgh cohort were also included in analysis for evaluating clinical correlations. Results. By protein immunoprecipitation assay, 6 SSc sera (1.9%) reacted with doublets with molecular weights around 50 kDa. Liquid chromatography‐mass spectrometry of the partially purified autoantigen and additional immunoblot‐based analyses revealed that this antibody specificity recognized RuvBL1/2. Anti‐RuvBL1/2 antibody was exclusively detected in SSc patients. SSc patients with anti‐RuvBL1/2 in both Japanese and Pittsburgh cohorts consistently had higher frequencies of SSc in overlap with myositis and diffuse skin thickening than did those without. Compared with other autoantibodies related to SSc‐myositis overlap (anti‐PM‐Scl and anti‐Ku), anti‐RuvBL1/2 was distinctive in terms of its associations with older age at SSc onset, male sex, and a high frequency of diffuse cutaneous involvement. Conclusions. Anti‐RuvBL1/2 antibody is a novel SSc‐related autoantibody associated with a unique combination of clinical features, including myositis overlap and diffuse cutaneous involvement. © 2013 American College of Rheumatology.


  • Open Access

    Detection of Circulating B Cells Producing Anti-GPIb Autoantibodies in Patients with Immune Thrombocytopenia

    by Masataka Kuwana, Yuka Okazaki, Yasuo Ikeda

    We previously reported that an enzyme-linked immunospot (ELISPOT) assay for detecting anti-GPIIb/IIIa antibody-secreting B cells is a sensitive method for identifying patients with immune thrombocytopenia (ITP). Here we assessed the clinical significance of measuring circulating B cells producing antibodies to GPIb, another major platelet autoantigen. Anti-GPIb and anti-GPIIb/IIIa antibody-producing B cells were simultaneously measured using ELISPOT assays in 32 healthy controls and 226 consecutive thrombocytopenic patients, including 114 with primary ITP, 25 with systemic lupus erythematosus (SLE), 30 with liver cirrhosis, 39 with post-hematopoietic stem cell transplantation (post-HSCT), and 18 non-ITP controls (aplastic anemia and myelodysplastic syndrome). There were significantly more circulating anti-GPIb and anti-GPIIb/IIIa antibody-producing B cells in primary ITP, SLE, liver cirrhosis, and post-HSCT patients than in healthy controls (PHelicobacter pylori infection, positive anti-nuclear antibody, and poor therapeutic response to intravenous immunoglobulin. The ELISPOT assay for detecting anti-GPIb antibody-secreting B cells is useful for identifying patients with ITP, but its utility for diagnosing ITP is inferior to the anti-GPIIb/IIIa ELISPOT assay. Nevertheless, detection of the anti-GPIb antibody response is useful for subtyping patients with primary ITP.


  • IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment

    by Yuichiro Shirai, Yuichi Tamura, Hidekata Yasuoka, Toru Satoh, Masataka Kuwana


  • Open Access

    Helicobacter pylori-associated immune thrombocytopenia: Clinical features and pathogenic mechanisms

    by Masataka Kuwana

    Immune thrombocytopenia (ITP) is an autoimmune disease mediated by anti-platelet autoantibodies. There is growing evidence that the eradication of Helicobacter pylori (H. pylori) effectively increases platelet count in a considerable proportion of ITP patients infected with this bacterium. In the majority of ITP patients responding to H. pylori eradication therapy, the anti-platelet autoantibody response is completely resolved with no relapse for more than 7 years, indicating that the disease is cured. Therefore, adult patients with suspected ITP should be examined for H. pylori infection, and eradication therapy is recommended if the infection is present. Notably, however, the efficacy of H. pylori eradication therapy in ITP patients varies widely among countries, with a higher response rate in Japan compared with the United States and European countries other than Italy. The pathogenesis of H. pylori-associated ITP is still uncertain, although the mechanisms are known to involve multiple factors. H. pylori may modulate the Fcγ-receptor balance of monocytes/macrophages in favor of activating Fcγ receptors, and H. pylori components may mimic the molecular makeup of platelet antigens. Further studies of the pathogenic process of H. pylori-associated ITP may be useful for the development of new therapeutic strategies for ITP.


  • Open Access

    Brief Report: Impaired In Vivo Neovascularization Capacity of Endothelial Progenitor Cells in Patients With Systemic Sclerosis

    by Masataka Kuwana, Yuka Okazaki

    Objective: Defective vasculogenesis is thought to play a role in the pathogenesis of systemic sclerosis (SSc). We undertook this study to explore the in vivo functional capacity of CD34+CD133+CD309+ endothelial progenitor cells (EPCs) in SSc patients.Methods: CD133+ cells and EPCs were enumerated by flow cytometry. Immunomagnetically sorted circulating CD133+ cells from 16 patients with SSc and 12 healthy subjects, as well as murine colon carcinoma CT‐26 cells, were transplanted beneath the skin of SCID mice. Tumor volume and blood vessel density were measured 10 days later. Human EPC incorporation into the vascular wall was evaluated using tumor sections double stained for mouse CD31 and human CD31.Results: The number of CD133+ cells and EPCs was significantly decreased in SSc patients as compared to healthy controls (P = 0.001 and P = 0.02, respectively), while the proportion of EPCs in CD133+ cells was similar between the 2 groups. CT‐26 cells produced markedly stronger tumor growth and neovessel formation when transplanted with CD133+ cells from healthy subjects than when transplanted with CD133+ cells from SSc patients (P = 0.001 and P = 0.008, respectively). Tumors from mice that received transplants of CT‐26 cells and SSc‐derived CD133+ cells formed fewer vessels incorporating human EPC–derived mature endothelial cells than did tumors from mice that received transplants of CT‐26 cells and CD133+ cells from healthy control subjects (P = 0.0002).Conclusion: We established a system that can be used to evaluate the in vivo neovascularization capacity of freshly isolated EPCs. EPCs contribute to vascularization by incorporating into vessel walls and by differentiating into endothelial cells. These EPC functions are impaired in SSc.


  • Open Access

    Platelet-Derived Stromal Cell-Derived Factor-1 Is Required for the Transformation of Circulating Monocytes into Multipotential Cells

    by Noriyuki Seta, Yuka Okazaki, Hiroshi Miyazaki, Takashi Kato, Masataka Kuwana

    We previously described a primitive cell population derived from human circulating CD14+ monocytes, named monocyte-derived multipotential cells (MOMCs), which are capable of differentiating into mesenchymal and endothelial lineages. To generate MOMCs in vitro, monocytes are required to bind to fibronectin and be exposed to soluble factor(s) derived from circulating CD14− cells. The present study was conducted to identify factors that induce MOMC differentiation. We cultured CD14+ monocytes on fibronectin in the presence or absence of platelets, CD14− peripheral blood mononuclear cells, platelet-conditioned medium, or candidate MOMC differentiation factors. The transformation of monocytes into MOMCs was assessed by the presence of spindle-shaped adherent cells, CD34 expression, and the potential to differentiate in vitro into mesenchymal and endothelial lineages. The presence of platelets or platelet-conditioned medium was required to generate MOMCs from monocytes. A screening of candidate platelet-derived soluble factors identified stromal cell-derived factor (SDF)-1 as a requirement for generating MOMCs. Blocking an interaction between SDF-1 and its receptor CXCR4 inhibited MOMC generation, further confirming SDF-1′s critical role in this process. Finally, circulating MOMC precursors were found to reside in the CD14+CXCR4high cell population. The interaction of SDF-1 with CXCR4 is essential for the transformation of circulating monocytes into MOMCs.